» Articles » PMID: 34490250

Construction and Analysis of a Colorectal Cancer Prognostic Model Based on N6-Methyladenosine-Related LncRNAs

Overview
Specialty Cell Biology
Date 2021 Sep 7
PMID 34490250
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

Given the relatively poor understanding of the expression and functional effects of the N6-methyladenosine (m6A) RNA methylation on colorectal cancer (CRC), we attempted to measure its prognostic value and clinical significance. We comprehensively screened 37 m6A-related prognostic long non-coding RNAs (lncRNAs) with significant differences in expression based on 21 acknowledged regulators of m6A modification and data on 473 colorectal cancer tissues and 41 para-cancer tissues obtained from the TCGA database. Accordingly, we classified 473 CRC patients into two clusters by consensus clustering on the basis of significantly different survival outcomes. We also found a potential correlation between m6A-related prognostic lncRNAs and BRAF-KRAS expression, as well as immune cell infiltration. Then, we established a prognostic model by selecting 16 m6A-related prognostic lncRNAs via LASSO Cox analysis and grouped the CRC patients into low- and high-risk groups to calculate risk scores. Then, we performed stratified sampling to validate and confirm our model by categorising the 473 samples into a training group ( = 208) and a testing group ( = 205) in a 1:1 ratio. The survival curve showed a distinct clinical outcome in the low- and high-risk subgroups. We reconfirmed the reliability and independence of the prognostic model through various measures: risk curve, heat map and univariate and multivariate Cox analyses. To ensure that the outcomes were applicable to clinical settings, we performed stratified analyses on different clinical features, such as age, lymph node status and clinical stage. CRC patients with downregulated m6A-related gene expression, lower immune score, distant metastasis, lymph node metastasis or more advanced clinical staging had higher risk scores, indicating less-desirable outcomes. Moreover, we explored the immunology of colorectal cancer cells. The risk score showed positive correlations with eosinophils, M2 macrophages and neutrophils. In summary, our effort revealed the significance of m6A RNA methylation regulators in colorectal cancer, and the prognostic model we constructed may be used as an essential reference for predicting the outcome of CRC patients.

Citing Articles

mC related-regulator-mediated methylation modification patterns and prognostic significance in breast cancer.

Wang Z, Li J, Wang F, Cheng C, Wu X, Guo W Sci Rep. 2024; 14(1):27477.

PMID: 39523404 PMC: 11551150. DOI: 10.1038/s41598-024-77389-4.


Development of a novel colon adenocarcinoma m6A-related lncRNA pair prognostic model.

Liang S, Qiu X, Cai L, Wei F, Huang J, Liu S Transl Cancer Res. 2024; 13(7):3704-3717.

PMID: 39145089 PMC: 11319945. DOI: 10.21037/tcr-23-1883.


Interaction of the intestinal cytokines-JAKs-STAT3 and 5 axes with RNA N6-methyladenosine to promote chronic inflammation-induced colorectal cancer.

Esmaeili N, Bakheet A, Tse W, Liu S, Han X Front Oncol. 2024; 14:1352845.

PMID: 39136000 PMC: 11317299. DOI: 10.3389/fonc.2024.1352845.


Ramifications of m6A Modification on ncRNAs in Cancer.

Mehmood R Curr Genomics. 2024; 25(3):158-170.

PMID: 39087001 PMC: 11288162. DOI: 10.2174/0113892029296712240405053201.


Analysis of disulfidptosis- and cuproptosis-related LncRNAs in modulating the immune microenvironment and chemosensitivity in colon adenocarcinoma.

Fan Q, Wu G, Chen M, Zheng L, Li H, Xiang L IET Syst Biol. 2024; 18(2):55-75.

PMID: 38458989 PMC: 10996446. DOI: 10.1049/syb2.12089.


References
1.
Qi P, Xu M, Ni S, Shen X, Wei P, Huang D . Down-regulation of ncRAN, a long non-coding RNA, contributes to colorectal cancer cell migration and invasion and predicts poor overall survival for colorectal cancer patients. Mol Carcinog. 2014; 54(9):742-50. DOI: 10.1002/mc.22137. View

2.
Wang Y, Lu J, Wu Q, Jin Y, Wang D, Chen Y . LncRNA LINRIS stabilizes IGF2BP2 and promotes the aerobic glycolysis in colorectal cancer. Mol Cancer. 2019; 18(1):174. PMC: 6886219. DOI: 10.1186/s12943-019-1105-0. View

3.
Xie Y, Gu J, Qin Z, Ren Z, Wang Y, Shi H . Long non-coding RNA FAM66C is associated with clinical progression and promotes cell proliferation by inhibiting proteasome pathway in prostate cancer. Cell Biochem Funct. 2020; 38(8):1006-1016. DOI: 10.1002/cbf.3531. View

4.
Wu Y, Yang X, Chen Z, Tian L, Jiang G, Chen F . mA-induced lncRNA RP11 triggers the dissemination of colorectal cancer cells via upregulation of Zeb1. Mol Cancer. 2019; 18(1):87. PMC: 6461827. DOI: 10.1186/s12943-019-1014-2. View

5.
Shen X, Ling X, Lu H, Zhou C, Zhang J, Yu Q . Low expression of microRNA-1266 promotes colorectal cancer progression via targeting FTO. Eur Rev Med Pharmacol Sci. 2018; 22(23):8220-8226. DOI: 10.26355/eurrev_201812_16516. View